Fabry disease and GLA variant-related care
Clinical research in Fabry disease centers on patients with amenable GLA variants, including adults and children, with attention to treatment use in the setting of renal impairment and end-stage renal disease requiring hemodialysis. The sponsor also studies migalastat in populations where kidney function may affect therapeutic management.
- Pharmacokinetics of migalastat
- Severe renal impairment
- End-stage renal disease
- Pediatric Fabry disease
Interest extends across age groups, with pediatric evaluation of Fabry disease and ongoing attention to treatment tolerability in metabolically and renally complex patients.
Late-onset Pompe disease
Research in late-onset Pompe disease includes adult subjects and reflects a focus on long-term treatment use in lysosomal storage disorder care. The sponsor studies ATB200 with AT2221 and cipaglucosidase alfa with miglustat in relation to safety and treatment performance.
- ATB200/AT2221 co-administration
- Cipaglucosidase alfa and miglustat
- Adult Pompe disease
- Tolerability in chronic therapy
This area includes attention to both biochemical support strategies and clinical use in adults living with Pompe disease.
Infantile-onset Pompe disease in children
Paediatric research covers infantile-onset Pompe disease from infancy through adolescence, including both enzyme replacement therapy-experienced and ERT-naïve children. The sponsor evaluates cipaglucosidase alfa/miglustat as a treatment approach in very young patients with Pompe disease.
- Infantile-onset Pompe disease
- Paediatric treatment
- ERT-experienced children
- ERT-naïve children
Clinical interest spans early childhood to late adolescence, with emphasis on treatment use in a rare neuromuscular metabolic condition.
Paediatric lysosomal storage disorders
The sponsor’s portfolio includes paediatric studies across lysosomal storage disorders, especially Fabry disease and Pompe disease. These trials address treatment considerations in younger patients where growth, developmental stage, and organ involvement may influence care.
- Children with Fabry disease
- Children with Pompe disease
- Age-specific treatment use
- Rare metabolic disease
Research activity in this area reflects sustained attention to therapies for inherited disorders affecting enzyme function and cellular metabolism.
